Shares in Verici Dx PLC (AIM:VRCI) surged 23% in early trading on Monday after the diagnostics company reported encouraging progress in the commercial rollout of its Tutivia test for kidney transplant patients and announced changes to its board.
The London-listed group said it had onboarded nine new transplant centres in the United States during the third quarter, taking the total to 30.
These centres now represent around 16% of annual US transplants. The number of clinicians ordering Tutivia, which detects early signs of organ rejection, rose by 19% over the period.
Verici said it expects sales volumes to accelerate in the final quarter of the year as newly signed centres begin testing patients. The company has expanded its commercial team with three senior sales hires and will appoint a director of clinical partnerships later this month.
The company said it remains on course to meet full-year market expectations.
In a separate statement, Verici said Aubrey Powell has joined the board as a non-executive director, replacing Dr Erik Lium, who steps down after four years representing Mount Sinai.
The shares rose 0.15p to 0.80p.